GPBAR1 and hepatocellular carcinoma: While direct evidence linking TGR5 levels to HCC progression is lacking, clinical serum samples analysis suggests that hypermethylation of the TGR5 promoter could serve as a potential biomarker to diagnose HBV-associated HCC.